| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Timothy E Morris is Director at DBVT. Timothy E Morris's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $121K at current prices.
Net of sales, the DBVT filings show accumulation of 12,000 shares.
Timothy E Morris has 12 Form 4 filings on record from April 2015 to June 2026, across 4 companies: Director at Aquestive Therapeutics (AQST), 2022–2026; Director at DBV Technologies (DBVT), 2021–2023; Chief Financial Officer at Iovance Biotherapeutics (IOVA), 2017–2019, and 1 more.
The 12 reported transactions were 10 option or other derivative awards and 2 open-market purchases.
Counted by filing, the open-market trades come to 1 purchase worth about $18K and no sales.
The only open-market purchase was 12,000 shares of DBVT at an average $1.52 on August 25, 2023, about $18K. Twelve months later DBVT was down 69%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 25, 2023 | DBVT Dbv Technologies S.A. | Director | Buy | 12,000 | $1.52 | $18,240.00 | New | -46.3% | -69.1% |